Jim Cramer -- Isis Pharma Deal With Bayer Is Huge; Avoid Tesla

NEW YORK (TheStreet) -- After initially being halted on Monday morning, shares of Isis Pharmaceuticals (ISIS) are rallying 4.5% after signing a $155 million deal with Bayer

The company's thrombosis drug is very important, as it acts as a blood thinner without causing the patient to bleed out, TheStreet's Jim Cramer, portfolio manager of the Action Alerts PLUS portfolio, said on CNBC's "Stop Trading" segment. 

This is a very big drug and a very big milestone, but investors should wait to hear what Dr. Stanley Crooke has to say when the company's CEO meets with Cramer on tonight's "Mad Money" TV show. 

TSLA Chart
Tesla Motors TSLA data by YCharts

Turning to Tesla Motors (TSLA), Cramer says the stock has become a "battleground" between bulls and bears. Investors seem to expect weak earnings results from the automaker when it reports on Wednesday after the close. 

With these types of companies that have a lot of potential but also a very high valuation, investors either buy into the story or they don't. Right now, there don't seem to be a lot of people buying in, Cramer said. 

If you liked this article you might like

The 12 Most Ridiculous Kitchen Appliances You Can Buy From Amazon

Tesla Shorts Beware; Traditional Media Makes a Comeback, -ICYMI

Tesla Is Dropping but Now Is One of the Worst Times to Be Short

Tesla to Discontinue Production of Cheaper Model S

Wall Street Deflates in Pullback After Fed Excitement, No Records for Dow